Merel Willekes

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

R. Stam, R. Pieters, E. Driessen, 2016, Oncotarget.

MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL

R. Stam, R. Pieters, P. Schneider, 2014, Cell cycle.

Clinical and molecular genetic characterization of wild-type MLL infant acute lymphoblastic leukemia identifies few recurrent abnormalities

R. Stam, M. D. Den Boer, R. Pieters, 2016, Haematologica.

MLL Fusion Driven Activation of CDK6 Potentiates Proliferation in MLL-rearranged Infant ALL

R. Stam, R. Pieters, P. Schneider, 2012 .

MLL fusion-driven activation of CDK6 potentiates proliferation in MLL-rearranged infant ALL

R. Stam, R. Pieters, P. Schneider, 2014, Cell cycle.